HLA-identical sibling peripheral blood progenitor cell transplants (PBPCT).
Peripheral blood progenitor cells (PBPC) are being investigated as an alternative stem cell source in allogeneic transplantation. The current paper presents a 'state-of-the-art' review of HLA-identical sibling transplants (PBPCT). Medline search and meeting reports were used to identify the latest reports from the various transplant centers. The data are presented systematically with the goal of providing a basis for evidence-based medicine. This approach offered the opportunity to identify threshold CD34+ cell numbers for rapid engraftment, threshold CD3+ cell numbers to prevent acute GVHD, prognostic factors for various outcome parameters and are a strong indication that the infused CD3+ cell dose might influence chronic graft-versus-host disease (GVHD), the most controversial and concerning aspect in allogeneic PBPCT. The value of systematic reviews for future clinical research planning is emphasized.
Van Hoef
M E
ME
TransOnc Consulting, Arlington, VA, USA.
D006680:HLA Antigens / Q000235:genetics*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006650:Histocompatibility Testing; D006801:Humans; D009679:Nuclear Family
D006680:HLA Antigens